Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management Guidelines

REFERENCES

• Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013.
   PubMed Web of Science ®Google Scholar
• Aydin Kurna S, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study. J Ophthalmol. 2014;2014:1–8. doi:10.1155/2014/460483.
   Web of Science ®Google Scholar
• Actis AG, Rolle T. Ocular surface alterations and topical antiglaucomatous therapy: a review. Open Ophthalmol J. 2014;8:67. doi:10.2174/1874364101408010067.
   PubMedGoogle Scholar
• Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28(3):93–103. doi:10.1080/15569520902995834.
   PubMed Web of Science ®Google Scholar
• Saini M, Vanathi M, Dada T, Agarwal T, Dhiman R, Khokhar S. Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy. Int J Ophthalmol. 2017;10(6):931. doi:10.18240/ijo.2017.06.16.
   PubMed Web of Science ®Google Scholar
• Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205–215. doi:10.1007/BF02853166.
   PubMed Web of Science ®Google Scholar
• Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids, and periorbital tissue. Drugs Aging. 2011;28(4):267–282. doi:10.2165/11588830-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355. doi:10.1097/IJG.0b013e31815c5f4f.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b2.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111(1):45–52. doi:10.1016/j.ophtha.2003.03.001.
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication: II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446–1454. doi:10.1001/archopht.1994.01090230060021.
   PubMedGoogle Scholar
• Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication: i. The conjunctival cell profile. Arch Ophthalmol. 1994;112(11):1437–1445. doi:10.1001/archopht.1994.01090230051020.
   PubMedGoogle Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7):716–726. doi:10.1111/j.1755-3768.2008.01250.x.
   PubMed Web of Science ®Google Scholar
• Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108(11):1543–1548. doi:10.1001/archopht.1990.01070130045027.
   PubMedGoogle Scholar
• Pérez-Bartolomé F, Martínez-de-la-Casa JM, Arriola-Villalobos P, Fernández-Pérez C, Polo V, García-Feijoó J. Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol. 2017;27(6):694–704. doi:10.5301/ejo.5000977.
   PubMed Web of Science ®Google Scholar
• Ramli N, Supramaniam G, Samsudin A, Juana A, Zahari M, Choo MM. Ocular surface disease in glaucoma: effect of polypharmacy and preservatives. Optometry Vision Sci. 2015;92(9):e222–e226. doi:10.1097/OPX.0000000000000542.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27(11):837–845. doi:10.1007/s12325-010-0070-1.
   PubMed Web of Science ®Google Scholar
• Rolando M, Crider JY, Kahook MY. Ophthalmic preservatives: focus on polyquaternium-1. Expert Opin Drug Deliv. 2011;8(11):1425–1438. doi:10.1517/17425247.2011.617736.
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Riancho L, Liang H, Baudouin C. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res. 2011;36(11):979–988. doi:10.3109/02713683.2011.578781.
   PubMed Web of Science ®Google Scholar
• Britt M, Burnstine MA. Iopidine allergy causing lower eyelid ectropion progressing to cicatricial entropion. British J Ophthalmol. 1999;83(8):987. doi:10.1136/bjo.83.8.987f.
   Web of Science ®Google Scholar
• Armisen M, Vidal C, Quintans R, Suarez A, Castroviejo M. Allergic contact dermatitis from apraclonidine. Contact Dermatitis. 1998;39(4):193. doi:10.1111/j.1600-0536.1998.tb05893.x.
   PubMed Web of Science ®Google Scholar
• Scruggs J, Whiteside-Michel J, Brodsky MC. The teardrop sign: a rare dermatological reaction to brimonidine. British J Ophthalmol. 2000;84(6):667. doi:10.1136/bjo.84.6.667e.
   Web of Science ®Google Scholar
• Kalavala M, Statham B. Allergic contact dermatitis from timolol and dorzolamide eye drops. Contact Dermatitis. 2006;54(6):345. doi:10.1111/j.0105-1873.2006.0645b.x.
   PubMed Web of Science ®Google Scholar
• Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141(2):264–273. doi:10.1046/j.1365-2133.1999.02974.x.
   PubMed Web of Science ®Google Scholar
• Lai C-H, Lai I-C, Chi -C-C. Allergic Contact Dermatitis Caused by Latanoprost Ophthalmic Solution. London, England: SAGE Publications Sage UK; 2006.
   Google Scholar
• Zimmerman TJ, Wheeler TM. Side effects and ways to avoid them. Ophthalmology. 1982;89(1):76–80. doi:10.1016/S0161-6420(82)34866-6.
   PubMed Web of Science ®Google Scholar
• Cusano F, Luciano S, Capozzi M, Verrilli D. Contact dermatitis from pilocarpine. Contact Dermatitis. 1993;29(2):99. doi:10.1111/j.1600-0536.1993.tb03495.x.
   PubMed Web of Science ®Google Scholar
• Reynolds A, Murray P, Colloby P. Darkening of eyelashes in a patient treated with latanoprost. Eye. 1998;12(4):741–743. doi:10.1038/eye.1998.181.
   PubMedGoogle Scholar
• Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):544–547. doi:10.1016/S0002-9394(14)70870-0.
   PubMed Web of Science ®Google Scholar
• Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol. 1995;113(3):293–296. doi:10.1001/archopht.1995.01100030047020.
   PubMedGoogle Scholar
• Wilkerson M, Lewis RA, Shields MB. Follicular conjunctivitis associated with apraclonidine. Am J Ophthalmol. 1991;111(1):105–106. doi:10.1016/S0002-9394(14)76907-7.
   PubMed Web of Science ®Google Scholar
• Adamsons IA, Polis A, Ostrov CS, Boyle JE. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide safety study group. J Glaucoma. 1998;7(6):395–401. doi:10.1097/00061198-199812000-00007.
   PubMed Web of Science ®Google Scholar
• Gupta R, Vernon S. An unusual appearance of limbal conjunctival follicles in a patient on brimonidine and dorzolamide. Eye. 2005;19(3):356–358. doi:10.1038/sj.eye.6701498.
   PubMed Web of Science ®Google Scholar
• Jackson WB. Differentiating conjunctivitis of diverse origins. Surv Ophthalmol. 1993;38:91–104. doi:10.1016/0039-6257(93)90034-5.
   PubMed Web of Science ®Google Scholar
• Dog˘ an AL, Orhan M, Söylemezog˘ Lu F, İrkeç M, Bozkurt B. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Exp Ophthalmol. 2004;32(1):62–66. doi:10.1046/j.1442-9071.2003.00760.x.
   PubMed Web of Science ®Google Scholar
• Pérez Bartolomé F, Martínez de la Casa JM, Arriola Villalobos P, Fernández Pérez C, Polo V, Sánchez Jean R, and García Feijoó J. Ocular Redness Measured with the Keratograph 5M in Patients Using Anti-Glaucoma Eye Drops. Semin Ophthalmol. 2018;33(5):643–650. doi:10.1080/08820538.2017.1395891.
   PubMed Web of Science ®Google Scholar
• Weissman S, Asbell P. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. British J Ophthalmol. 1990;74(7):409–412. doi:10.1136/bjo.74.7.409.
   PubMed Web of Science ®Google Scholar
• Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol. 1979;88(4):739–743. doi:10.1016/0002-9394(79)90675-5.
   PubMed Web of Science ®Google Scholar
• Wirtitsch MG, Findl O, Heinzl H, Drexler W. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. Arch Ophthalmol. 2007;125(10):1345–1350. doi:10.1001/archopht.125.10.1345.
   PubMedGoogle Scholar
• Ammar DA, Kahook MY. The effects of combination glaucoma medications on ocular surface epithelial cells. Adv Ther. 2009;26(10):970–975. doi:10.1007/s12325-009-0076-8.
   PubMed Web of Science ®Google Scholar
• Edwards R. A comparative study of Ocuserta® Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma. Curr Med Res Opin. 1997;13(9):501–509. doi:10.1185/03007999709113323.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Kenyon KR, Epstein DL, Van Buskirk EM. Corneal changes during pilocarpine gel therapy. Am J Ophthalmol. 1986;101(1):13–15. doi:10.1016/0002-9394(86)90459-9.
   PubMed Web of Science ®Google Scholar
• Massry GG, Assil KK. Pilocarpine-associated allograft rejection in postkeratoplasty patients. Cornea. 1995;14(2):202–205. doi:10.1097/00003226-199503000-00015.
   PubMed Web of Science ®Google Scholar
• Morales J, Shihab ZM, Brown SM, Hodges MR. Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol. 2001;132(1):114–116. doi:10.1016/S0002-9394(01)01012-1.
   PubMed Web of Science ®Google Scholar
• Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41:S129–S138. doi:10.1016/S0039-6257(97)80020-3.
   PubMed Web of Science ®Google Scholar
• Narioka J, Ohashi Y. Effects of beta-adrenergic antagonist on width of nasolacrimal drainage system lumen. J Ocul Pharmacol Ther. 2007;23(5):467–475. doi:10.1089/jop.2007.0025.
   PubMed Web of Science ®Google Scholar
• Gipson IK, Argüeso P, Beuerman R, et al. Research in dry eye: report of the research subcommittee of the international dry eye workShop (2007). Ocul Surf. 2007;5:179–193.
   PubMed Web of Science ®Google Scholar
• Pinho Tavares F, Fernandes RS, Bernardes TF, and Bonfioli AA. Carneiro Soares EJ Dry eye disease. Seminars in Ophthalmology. Vol. 25. Taylor & Francis; 2010:84–93.
   Google Scholar
• Wong AB, Wang MT, Liu K, Prime ZJ, Danesh-Meyer HV, Craig JP. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf. 2018;16(3):289–293. doi:10.1016/j.jtos.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid: a spectrum of diseases. Arch Ophthalmol. 1987;105(12):1660–1663. doi:10.1001/archopht.1987.01060120058023.
   PubMedGoogle Scholar
• Bernauer W, Broadway DC, Wright P. Chronic progressive conjunctival cicatrisation. Eye. 1993;7(3):371–378. doi:10.1038/eye.1993.75.
   PubMedGoogle Scholar
• Nelson JD. Impression cytology. Cornea. 1988;7(1):71–81. doi:10.1097/00003226-198801000-00012.
   PubMed Web of Science ®Google Scholar
• Hong S, Lee CS, Seo KY, Seong GJ, Hong YJ. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006;142(1):185–186. doi:10.1016/j.ajo.2006.02.056.
   PubMed Web of Science ®Google Scholar
• Brandt JD, Wittpenn JR, Katz LJ, Steinmann WN, Spaeth GL. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol. 1991;112(3):297–301. doi:10.1016/S0002-9394(14)76730-3.
   PubMed Web of Science ®Google Scholar
• Nuzzi R, Finazzo C, Vercelli A, Cracco C. Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol. 1995;233(3):154–162. doi:10.1007/BF00166608.
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Grierson I, Milgar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96(3):327–335. doi:10.1016/S0161-6420(89)32888-0.
   PubMed Web of Science ®Google Scholar
• Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica. 2002;216(3):175–179. doi:10.1159/000059624.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101(3):454–460. doi:10.1016/S0161-6420(94)31322-4.
   PubMed Web of Science ®Google Scholar
• Guglielminetti E, Barabino S, Monaco M, Mantero S, Rolando M. HLA-DR expression in conjunctival cells after latanoprost. J Ocul Pharmacol Ther. 2002;18(1):1–9. doi:10.1089/108076802317233162.
   PubMed Web of Science ®Google Scholar
• Huang LC, Wong JR, Alonso-Llamazares J, et al. Pseudopemphigoid as caused by topical drugs and pemphigus disease. World J Ophthalmol. 2015;5(1):1–15. doi:10.5318/wjo.v5.i1.1.
   Google Scholar